E-MAIL UPDATES

Click here to join
our Electronic Communications.

Listen to a replay of the Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” that took place on Wednesday, June 26, 2019

Who we are?

Management.

Team - Marc Voigt

Marc Voigt

Executive Director & Chief Executive Officer (CEO)

Team - Frederic Triebel

Frédéric Triebel, MD Ph.D.

Chief Scientific Officer & Chief Medical Officer

Team - Deanne Miller

Deanne Miller

Chief Operating Officer, General Counsel & Company Secretary

Team - Jay Campbell

Jay R. Campbell

Chief Business Officer (CBO)

Team - Christian Mueller

Christian Mueller

Director Clinical Development and Regulatory Affairs

Team - Michael Buchholz

Michael Buchholz, Ph.D.

Director of Manufacturing

Team - Claudia Jacoby

Claudia Jacoby, Ph.D.

Director of Manufacturing

Team - James Flinn

James Flinn, Ph.D.

Intellectual Property and Innovation Director

Team - David Fang

David Fang

Finance Director & Assistant Company Secretary

Board.

Team - Russel Howard

Russell Howard, Ph.D.

Non-Executive Chairman

Team - Grant Chamberlain

Grant Chamberlain

Non-Executive Director

Team - Marc Voigt

Marc Voigt

Executive Director & Chief Executive Officer (CEO)

Team - Pete Meyers

Pete Meyers

Non-Executive Director and Deputy Chairman

Advisory board.

Dr. Luc Dirix

Prof. Salah-Eddin Al-Batran

Dr. Samson Fung

Prof. Martine J. Piccart

Prof. David Cameron